Financial Data and Key Metrics Changes - The company reported total revenue of $65.5 billion for the first quarter of 2025, with adjusted earnings per share (EPS) growing to $6.74, leading to an increase in full-year EPS guidance to at least $29.6 [9][32][36] - Net after-tax special item charges amounted to $229 million, or $0.84 per share, which included a charge of $163 million related to a strategic optimization program [6][10] Business Line Data and Key Metrics Changes - EverNorth's revenues grew to $53.7 billion, with pretax adjusted earnings increasing by 5% to $1.4 billion [32] - Specialty and Care Services within EverNorth saw a revenue increase of 19% to $23.9 billion, while pharmacy benefit services reported a 14% revenue growth [33][24] - Cigna Healthcare's revenues were $14.5 billion, with pretax adjusted earnings of $1.3 billion and a medical care ratio (MCR) of 82.2% [34] Market Data and Key Metrics Changes - The company noted strong demand for strategic partners in healthcare, driven by the unsustainable trajectory of U.S. healthcare expenditures, which exceed $4.5 trillion annually [11] - The specialty pharmacy market is experiencing attractive growth rates due to new drug introductions and increased adoption of biosimilars [22] Company Strategy and Development Direction - The company is focused on building a more sustainable healthcare model, addressing key areas such as access, support, value, accountability, and transparency [12][14] - Strategic acquisitions, partnerships, and divestitures are part of the company's ongoing portfolio management, with the recent sale of its Medicare business as a notable example [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver 10% to 14% compounded EPS growth over the strategic horizon, despite a dynamic and challenging environment [14][15] - The company anticipates elevated medical cost trends in 2025 but remains optimistic about its action plans to improve margins and overall performance [35] Other Important Information - The company has repurchased 8.2 million shares for approximately $2.6 billion, reflecting a disciplined capital management strategy [39] - The company is committed to enhancing customer experience and transparency, with positive stakeholder feedback on recent initiatives [25][24] Q&A Session Summary Question: Weight loss and GLP-1 pricing opportunities - Management discussed the comprehensive approach to GLP-1 programs and the potential for improved pricing as net pricing decreases in this class, with over 50% of employers providing coverage for weight management [42][48] Question: Economic environment impact on client discussions - Management noted that affordability remains a key focus for employers, with strong retention rates in the Express Scripts business and continued interest in personalized solutions [56][58] Question: Stop loss business performance and cost trends - Management confirmed that the stop loss margin improvement plan is on track, with elevated trends in specialty and behavioral categories observed in the first quarter [63][70] Question: Arkansas legislation and potential conflicts of interest - Management opposed the Arkansas bill, emphasizing the importance of maintaining choice and transparency in the marketplace [75][76] Question: Capital deployment and M&A strategy - Management reiterated a consistent capital deployment strategy focused on supporting business growth, with a priority on bolt-on acquisitions [84][88]

Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD As filed with the U.S. Securities and Exchange Commission on October 6, 2023 If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration ...

As filed with the U.S. Securities and Exchange Commission on August 31, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

As filed with the U.S. Securities and Exchange Commission on August 17, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

As filed with the U.S. Securities and Exchange Commission on July 21, 2023 Registration No. 333-272230 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organiza ...

As filed with the U.S. Securities and Exchange Commission on May 26, 2023 Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIMEI HEALTH TECHNOLOGY CO., LTD (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Aime ...